The　outbreak　of　the　novel　coronavirus　disease　2019　(COVID-19),　caused　by　the　severe　acute　respiratory　syndrome　coronavirus　2　(SARS-CoV-2),　has　caused　great　harm　to　all　countries　worldwide.　This　disease　can　be　prevented　by　vaccination　and　managed　using　various　treatment　methods,　including　injections,　oral　medications,　or　aerosol　therapies.　However,　the　selection　of　suitable　compounds　for　the　research　and　development　of　anti-SARS-CoV-2　drugs　is　a　daunting　task　because　of　the　vast　databases　of　available　compounds.　The　traditional　process　of　drug　research　and　development　is　time-consuming,　labour-intensive,　and　costly.　The　application　of　chemometrics　can　significantly　expedite　drug　R&D.　This　is　particularly　necessary　and　important　for　drug　development　against　pandemic　public　emergency　diseases,　such　as　COVID-19.　Through　various　chemometric　techniques,　such　as　quantitative　structure-activity　relationship　(QSAR)　modelling,　molecular　docking,　and　molecular　dynamics　(MD)　simulations,　compounds　with　inhibitory　activity　against　SARS-CoV-2　can　be　quickly　screened,　allowing　researchers　to　focus　on　the　few　prioritised　candidates.　In　addition,　the　ADMET　properties　of　the　screened　candidate　compounds　should　be　further　explored　to　promote　the　successful　discovery　of　anti-SARS-CoV-2　drugs.　In　this　case,　considerable　time　and　economic　costs　can　be　saved　while　minimising　the　need　for　extensive　animal　experiments,　in　line　with　the　3R　principles.　This　paper　focuses　on　recent　advances　in　chemometric　modelling　studies　of　COVID-19-related　inhibitors,　highlights　current　limitations,　and　outlines　potential　future　directions　for　development.